益生菌加维生素D在刺激性肠综合征:一个前性的多中心非干预性研究
Pauline Jouët1, Claude Altman2, Stanislas Bruley DES Varannes3
1Service of Gastroenterology, Avicenne Hospital, Bobigny, France - pauline.jouet@aphp.fr.
Minerva gastroenterology
|March 6, 2024
概括
这项研究表明,益生菌和维生素D的组合显著改善了患有刺激性肠综合征 (IBS) 的患者的症状和生活质量. 在现实临床实践中,治疗减少了IBS的严重程度和与肠道相关的焦虑.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 营养科学 营养科学
背景情况:
- 刺激性肠综合征 (IBS),特别是腹占主导 (IBS-D) 和混合 (IBS-M) 类型,由于复发症状和相关焦虑,显著损害患者的生活质量 (QoL).
- 目前的管理策略往往不足,需要探索新的治疗方法.
研究的目的:
- 评估特定益生菌和维生素D组合在改善诊断为IBS-D或IBS-M的患者日常临床实践结果方面的疗效.
- 评估这种干预对现实世界的症状严重程度,生活质量和焦虑水平的影响.
主要方法:
- 一项前性,多中心,非干预性研究,根据罗马四号标准,涉及IBS-D或IBS-M的成年患者.
- 参与者每天接受一袋含有三种益生菌菌株 (Lactobacillus plantarum CETC 7484和CETC 7485;Pediococcus acidilactici CECT 7483) 和维生素D (10微克) 的组合,持续42天.
- 主要终点:在第42天的响应率,定义为IBS-严重性评分系统 (IBS-SSS) 的≥50%和/或≥100点下降. 与肠道相关的焦虑是用视觉敏感度指数 (VSI) 来衡量的.
主要成果:
- 这项研究包括246名患者 (56.1%的IBS-D,43.9%的IBS-M;平均年龄为51.2岁).
- 在第42天,89名可评估患者的反应率为62.9%,IBS-SSS显著平均下降146.6点 (P<0.0001).
- 在IBS-SSS得分的改善与强化IBS-QoL (r=-0.78),减少HAD焦虑 (r=0.46),HAD抑郁 (r=0.61) 和VSI得分 (r=0.74) 强烈相关,所有得分均为P<0.001.1.
结论:
- 现实世界的数据支持益生菌和维生素D组合在IBS-D和IBS-M患者中的有益作用,与之前的随机试验一致.
- 症状缓解与整体体体质量,一般焦虑,抑郁症,特别是与肠道相关的焦虑症的显著改善直接相关.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163
Irritable Bowel Syndrome I: Introduction
273
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
273
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
160
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
160
Irritable Bowel Syndrome III: Medical and Nursing Management
204
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
204


